Skip to main content

Advertisement

SpringerLink
Log in

Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

C-reactive protein (CRP) was an independent prognostic factor for metastatic renal cell carcinoma in the cytokine era. However, the impact of CRP on the survival of metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors has not yet been investigated. Therefore, we further evaluated the prognostic impact of CRP for patients with metastatic renal cell carcinoma treated with molecular-targeted agents of tyrosine kinase inhibitors.

Methods

Fifty-two patients were treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma at our institution. Overall, 31 and 21 patients were administered sunitinib and sorafenib, respectively. The prognostic value of all variables, including CRP, for overall survival was assessed using the Cox proportional hazards model.

Results

The median baseline CRP level was 4.9 mg/l. In multivariate analysis, CRP was an independent predictor for overall survival as both continuous and categorical variable. The median overall survival times of patients with non-elevated CRP concentration (<8 mg/l) were not reached, compared with those of patients with elevated CRP concentration (8 mg/l or greater) of 15.9 months. There was a significant difference in overall survival rates between the two groups, with 1- and 3-year overall survival rates of 92.8 and 69.3 % versus 50.2 and 22.9 % for the non-elevated CRP group and the elevated CRP group (p = 0.003), respectively.

Conclusions

CRP has a significant impact on overall survival of patients with metastatic renal cell carcinoma carcinoma treated with tyrosine kinase inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115–124

    Article  PubMed  CAS  Google Scholar 

  2. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med 356:125–134

    Article  PubMed  CAS  Google Scholar 

  3. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111

    Article  PubMed  Google Scholar 

  4. Rini BI, Halabi S, Rosenberg JE et al (2008) CALGB 90206: a phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in metastatic renal cell carcinoma. Presented at the genitourinary cancers symposium, San Francisco, CA

  5. Palmer PA, Vinke J, Philip T et al (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3:475–480

    PubMed  CAS  Google Scholar 

  6. Negrier S, Escudier B, Gomez F et al (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann Oncol 13:1460–1468

    Article  PubMed  CAS  Google Scholar 

  7. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296

    Article  PubMed  CAS  Google Scholar 

  8. Atzpodien J, Royston P, Wandert T et al (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88:348–353

    Article  PubMed  CAS  Google Scholar 

  9. McMillan DC, Canna K, McArdle CS (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90:215–219

    Article  PubMed  CAS  Google Scholar 

  10. Heys SD, Ogston KN, Simpson WG et al (1998) Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival. Int J Oncol 13:589–594

    PubMed  CAS  Google Scholar 

  11. Guillem P, Triboulet JP (2005) Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 18:146–150

    Article  PubMed  CAS  Google Scholar 

  12. Bromwich E, McMillan DC, Lamb GW et al (2004) The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer 91:1236–1238

    Article  PubMed  CAS  Google Scholar 

  13. Casamassima A, Picciariello M, Quaranta M et al (2005) C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 173:52–55

    Article  PubMed  CAS  Google Scholar 

  14. Ramsey S, Lamb GW, Aitchison M et al (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109:205–212

    Article  PubMed  Google Scholar 

  15. Saito K, Tatokoro M, Fujii Y et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55:1145–1153

    Article  PubMed  CAS  Google Scholar 

  16. Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463

    Article  PubMed  Google Scholar 

  17. Choueiri TK, Garcia JA, Elson P et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543–550

    Article  PubMed  CAS  Google Scholar 

  18. Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799

    Article  PubMed  CAS  Google Scholar 

  19. Saito K, Kihara K (2010) Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev Anticancer Ther 10:1979–1989

    Article  PubMed  CAS  Google Scholar 

  20. Saito K, Kihara K (2011) C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 8:659–666

    PubMed  CAS  Google Scholar 

  21. Komai Y, Saito K, Sakai K et al (2007) Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99:77–80

    Article  PubMed  CAS  Google Scholar 

  22. Tatokoro M, Saito K, Iimura Y et al (2008) Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol 180:515–519

    Article  PubMed  CAS  Google Scholar 

  23. Iimura Y, Saito K, Fujii Y et al (2009) Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 181:1004–1012

    Article  PubMed  Google Scholar 

  24. Miki S, Iwano M, Miki Y et al (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250:607–610

    Article  PubMed  CAS  Google Scholar 

  25. Koo AS, Armstrong C, Bochner B et al (1992) Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother 35:97–105

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan

    Yosuke Yasuda, Takeshi Yuasa, Shinichi Kitsukawa, Shinji Urakami, Shinya Yamamoto, Junji Yonese & Iwao Fukui

  2. Department of Urology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

    Kazutaka Saito

  3. Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan

    Takeshi Yuasa & Shunji Takahashi

Authors
  1. Yosuke Yasuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazutaka Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeshi Yuasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinichi Kitsukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinji Urakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinya Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Junji Yonese
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shunji Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Iwao Fukui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazutaka Saito.

About this article

Cite this article

Yasuda, Y., Saito, K., Yuasa, T. et al. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 18, 884–889 (2013). https://doi.org/10.1007/s10147-012-0454-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-012-0454-0

Keywords

Search

Navigation